ReviewFrontiers in medicine2026
Interstitial lung abnormalities: a mechanistic window into early fibrotic lung disease.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interstitial lung abnormalities (ILAs) are incidental, non-dependent parenchymal abnormalities detected on chest computed tomography (CT) in individuals without a diagnosis of interstitial lung disease (ILD). Once regarded as non-specific or age-related findings, ILAs are increasingly recognized as clinically relevant entities associated with progression to fibrotic ILD and increased mortality. Emerging molecular and epidemiological evidence indicates that ILAs share key pathogenic pathways with idiopathic pulmonary fibrosis (IPF), the archetypal progressive fibrotic ILD, including alveolar epithelial cell (AEC) stress and injury, innate immune activation, dysregulated repair, fibroblast activation, extracellular matrix (ECM) remodeling, and aging-associated cellular dysfunction. These observations suggest that ILAs may represent the early stage in the continuum of fibrotic lung disease. As such, ILAs provide a valuable opportunity to uncover early disease mechanisms and novel therapeutic targets and enable identification of individuals at increased risk of progression before clinically overt ILD develops. This mini review summarizes emerging mechanistic insights into ILAs and discusses how understanding early disease biology may inform risk stratification and preventative therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.